The BioWorld Insider Podcast
One-on-one with medical innovators: Breakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating markets. BioWorld tracks key events in the fast-moving sector every business day. Now, the BioWorld Insider podcast lets you hear directly from the movers and shakers whose collective work is changing how we all live. Join us for a new conversation.
- Update frequency
- every 29 days
- Average duration
- 22 minutes
- Episodes
- 50
- Years Active
- 2021 - 2025
Trying this at home: Bioxcel steps closer to an sNDA for Igalmi – AUDIO
Bioxcel Therapeutics Inc.’s phase III results in bipolar disorders or schizophrenia could bring Igalmi (BXCL-501) out of the clinic and into patients' homes for easier treatment. Vimal Mehta, Bioxce…
The importance of balancing AI and people in drug development
More and more, artificial intelligence is becoming inseparable from drug development. But it needs to be well integrated with the right people and support technologies in order to be successful, acco…
Two CEOs discuss bracing for tariffs, NIH grant cuts and gifting China biopharma leadership position
As pharma deals with the impact of NIH grant cuts and what could follow with the imposition of tariffs, Robert Williamson, CEO of Triumvira Immunologics Inc., and Hernan Bazan, CEO of South Rampart…
As biopharma investments stumble, med tech surges
The biopharma sector is still trying to get its wind and resume its once-powerful investment ways. Medical technology has sidestepped much of biopharma’s issues by being more flexible along the devel…
Mega money well spent? Mammoth mergers fall short of the dream
Billion-dollar M&As are commonplace now, but not too long ago they were a rarity. So many have occurred in the past few years, they’ve become the norm. But were all these multi-billion-dollar mega me…
Healing the health divide for women
As a new BioWorld investigative report shows, decades of research excluding women from clinical trials and investment decisions made in male-dominated boardrooms have led to half the world’s health …
Modifi gets creative on the rocky road to a multibillion-dollar buyout
Modifi Biosciences Inc. was recently acquired by Merck & Co. Inc. for $30 million up front. Modifi shareholders could receive milestones of up to $1.3 billion. It all happened in the dizzyingly short…
A quantum leap into the future of drug development
In the newest BioWorld Insider podcast, Victoria Lipinska, the America's lead for Quantum Innovation Centers at IBM Quantum, talks about the future of drug development using quantum computing. “The n…
Gene and cell therapies will propel innovation, says Astellas CCO
Gene and cell therapies will drive innovation for the next 10 years, Claus Zieler, the chief commercial officer at Astellas Pharma Inc., said in this episode of the BioWorld Insider podcast. Develope…
Capricor’s CEO pursues a BLA and talks rare disease
Capricor Therapeutics Inc. just wrapped up a visit with the U.S. FDA and is prepping to file a BLA in October for its Duchenne muscular dystrophy treatment. Linda Marbán, Capricor’s CEO, is the guest…
The first half of 2024 was strong as M&As and financings dominate
Karen Carey, BioWorld managing editor and chief analyst, takes a look at the numbers from the first half of 2024. She finds the first six months to be healthy for the biopharma market while the rest …
The cost of delays in development and sales: It’s probably not what you think
Two costs of developing drug candidates have been upended by new research from the Tufts University School of Medicine’s Center for the Study of Drug Development. New data have produced some very dif…
ASCO preview: ADCs and radiotherapies at the forefront of this year’s conference
Chris Barden, a co-managing partner at MPM Bioimpact who manages the firm’s Bioimpact Equities and Oncology Impact funds, shares her insights into the upcoming American Society of Clinical Oncology (…
Fibrobiologics walks the unconventional financing path
A non-traditional route for financing has been the path to success for Fibrobiologics Inc. In the newest BioWorld Insider podcast, CEO Pete O’Heeron offers insight into the company’s unusual path to …
Back to fundamentals: The latest numbers point to better times
BioWorld Managing Editor Karen Carey joins the podcast to talk about the numbers from the first quarter of 2024, along with a look back at some 2023 deals and indicators that signal better times are …
Mark McKenna storms back with Mirador and eyes the development landscape
In one of the biggest financings of the year so far, former Prometheus Biosciences Inc. CEO Mark McKenna helped raise $400 million to launch a new company, Mirador Therapeutics Inc. He didn’t sit on …
Biopharma execs seek to avoid pain points in AI integration
Because artificial intelligence is such a new technology it comes with a mountain of unknowns. Integrating it into a pharmaceutical company presents a unique series of challenges, as a new survey fro…
Six biopharma executives consider a tough 2023 and are hopeful for a better 2024
One aspect of 2023 our group of executives completely agreed on: the past year was tough financially. And they all foresee a more vibrant year ahead for the market. Giving all of them hope were techn…
AI: driving drug development from effective to remarkable
Google’s Scott Penberthy joins the podcast for a visionary discussion that scans the horizon for startling changes artificial intelligence will bring to drug development in the relatively near futur…
The struggle is real: The first half of 2023 was an uphill climb
Guests Karen Carey, BioWorld’s managing editor, and Mike Ward, Clarivate’s global head of Life Sciences and Healthcare Thought Leadership, discuss the deals, financing and M&A landscape for the fir…